Mark G. Lebwohl, MD

Mark G. Lebwohl, MD, introduces the case of a 28-year-old female nurse with a long history of psoriasis, commenting on her past medical history and initial presentation.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide impressions to the case and take-home messages for dermatologists and rheumatologists treating psoriasis.

Mark G. Lebwohl, MD, presents a case of a 45-year-old Caucasian male diagnosed with psoriasis.

Drs Mark G. Lebwohl and Joseph F. Merola discuss the use of biosimilars in psoriasis and how biosimilars will change the treatment landscape.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide insight on when it is appropriate to switch from one biologic to another for a patient with psoriasis.

Expert dermatologists discuss different anti-TNF molecules and the impact of having these types of molecules on psoriasis and psoriatic arthritis care.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss different head-to-head studies in psoriasis.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide tips to overcome diagnostic delay in psoriasis.

Expert dermatologists discuss challenges in diagnosing a patient with PsA.

Drs Mark G. Lebwohl and Joseph F. Merola discuss how patient presentation differs in patients with PsO and PsA.

Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss updates in the pathogenesis of PsA and PsO.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.